Physical Sciences and Exact Sciences Technology Offers Page 3

Find the latest Innovations, Patents and Knowhow from top scientistsand innovators in Physical Sciences and Exact Sciences, Nanotechnology, Modelling and Optics

Physical Sciences, Exact Science but above all Nanotechnology is relied upon to be one of the technology areas with the highest research funding level in the sectors of physical sciences, exact sciences, chemistry, opctics and many other physical sciences applications and exact sciences. A large portion of the top ranking research organizations and innovation centers are investing resurces in the research and development of novel technologies in order to develop the next generation of technology solutions in the areas of physics, climatology or acoustic engineering. Find below the list of Technology Offers and already published innovations in nanotechnology, modelling, physical sciences and exact sciences.

RAMOT at Tel Aviv University Ltd. posted this:

Modulating T cells functions by down regulating specific genes using RNA interference (RNAi) holds tremendous potential in advancing targeted therapies in many immune related disorders including cancer, inflammation, autoimmunity and viral infections. Hematopoietic cells, in general, and primary T lymphocytes, in particular, are notoriously hard to transfect with small interfering RNAs (siRNAs). Herein, we describe a novel strategy to specifically deliver siRNAs to murine CD4+ T cells using targeted lipid nanoparticles (tLNPs). To increase the efficacy of siRNA delivery, these tLNPs have been formulated with several lipids designed to improve the stability and efficacy of siRNA delivery. The tLNPs were surface functionalized with anti-CD4 monoclonal antibody (mAb) to permit delivery of the siRNAs specifically to CD4+ T lymphocytes. Ex vivo, tLNPs demonstrated specificity by targeting only primary CD4+ T lymphocytes and no other cell types. Systemic intravenous administration of these particles led to efficient binding and uptake into CD4+ T lymphocytes in several anatomical sites including the spleen, inguinal lymph nodes, blood and the bone marrow. Silencing by tLNPs occur in a subset of circulating and resting CD4+ T lymphocytes. Interestingly, we show that tLNPs internalization and not endosome escape is a fundamental event that takes place as early as one hour after systemic administration that determine tLNPs efficacy. Taken together, these results suggest that tLNPs may open new avenues for the manipulation of T cell functionality and may help to establish RNAi as a therapeutic modality in leukocyte-associated diseases. Project ID : 10-2016-962